468 related articles for article (PubMed ID: 36921563)
1. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract][Full Text] [Related]
2. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.
Xu X; Sun Z; Liu Q; Zhang Y; Shen L; Zhang C; Lin H; Hu B; Rong L; Chen H; Wang X; Zhao X; Bai YR; Ye Q; Ma X
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458635
[TBL] [Abstract][Full Text] [Related]
4. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE).
Yan X; Duan H; Ni Y; Zhou Y; Wang X; Qi H; Gong L; Liu H; Tian F; Lu Q; Sun J; Yang E; Zhong D; Wang T; Huang L; Wang J; Chaoyang Wang ; Wang Y; Wan Z; Lei J; Zhao J; Jiang T
Int J Surg; 2022 Jul; 103():106680. PubMed ID: 35595021
[TBL] [Abstract][Full Text] [Related]
5. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
6. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC.
Li Y; Zhou A; Liu S; He M; Chen K; Tian Z; Li Y; Qin J; Wang Z; Chen H; Tian H; Yu Y; Qu W; Xue L; He S; Wang S; Bie F; Bai G; Zhou B; Yang Z; Huang H; Fang Y; Li B; Dai X; Gao S; He J
BMC Med; 2023 Mar; 21(1):86. PubMed ID: 36882775
[TBL] [Abstract][Full Text] [Related]
7. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China.
Hou H; Wang Y; Sun D; Zhu J; Jiang M; Zhang X; Zhou N; Zhang C; Li T; Zhang X
Invest New Drugs; 2023 Feb; 41(1):86-92. PubMed ID: 36508040
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial.
Zhang Z; Ye J; Li H; Gu D; Du M; Ai D; Chen W; Fang Y; Xu X; Bai C; Zhao K; Zhou G
Front Immunol; 2022; 13():1031171. PubMed ID: 36311804
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma.
Fan Y; Jiang Y; Zhou X; Chen Q; Huang Z; Xu Y; Gong L; Yu H; Yang H; Liu J; Lei T; Zhao Q; Mao W
Oncotarget; 2016 Aug; 7(31):50624-50634. PubMed ID: 27244882
[TBL] [Abstract][Full Text] [Related]
12. The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study.
Xing W; Zhao L; Zheng Y; Liu B; Liu X; Li T; Zhang Y; Ma B; Yang Y; Shang Y; Fu X; Liang G; Yuan D; Qu J; Chai X; Zhang H; Wang Z; Lin H; Liu L; Ren X; Zhang J; Gao Q
Front Immunol; 2021; 12():772450. PubMed ID: 34938292
[TBL] [Abstract][Full Text] [Related]
13. Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma.
Wang H; Jiang Z; Wang Q; Wu T; Guo F; Xu Z; Yang W; Yang S; Feng S; Wang X; Chen S; Cheng C; Chen W
Eur J Cancer; 2023 Jun; 186():196-210. PubMed ID: 37045666
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial.
Chen X; Xu X; Wang D; Liu J; Sun J; Lu M; Wang R; Hui B; Li X; Zhou C; Wang M; Qiu T; Cui S; Sun N; Li Y; Wang F; Liu C; Shao Y; Luo J; Gu Y
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759013
[TBL] [Abstract][Full Text] [Related]
15. Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial.
Yang G; Su X; Huang Y; Luo G; Wang Z; Cai P; Zheng Y; Bei T; Huang M; Bai Y; He H; Xiang J; Cai M; Zhong J; Guo Q; Zhang X
J Transl Med; 2023 Jun; 21(1):411. PubMed ID: 37355621
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma.
Yang W; Xing X; Yeung SJ; Wang S; Chen W; Bao Y; Wang F; Feng S; Peng F; Wang X; Chen S; He M; Zhang N; Wang H; Zeng B; Liu Z; Kidane B; Seder CW; Koyanagi K; Shargall Y; Luo H; Peng S; Cheng C
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022193
[TBL] [Abstract][Full Text] [Related]
17. Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial.
Jiang N; Zhang J; Guo Z; Wu Y; Zhao L; Kong C; Song X; Gu L; Zhao Y; Li S; He X; Ren B; Zhu X; Jiang M
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38199609
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma.
Xu H; Wang W; Yin J; Song C; Li L; Sun Z
Drug Des Devel Ther; 2022; 16():4269-4277. PubMed ID: 36540715
[TBL] [Abstract][Full Text] [Related]
19. Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.
Yang Y; Li H; Chen X; Qin J; Li Y; Shen Y; Zhang R; Kang X; Wang Z; Zheng Q; Luo P; Li Y; He J
Thorac Cancer; 2023 Mar; 14(7):700-708. PubMed ID: 36788648
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001).
Shang X; Zhao G; Liang F; Zhang C; Zhang W; Liu L; Li R; Duan X; Ma Z; Yue J; Chen C; Meng B; Ren X; Jiang H
Ann Transl Med; 2022 Feb; 10(4):229. PubMed ID: 35280363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]